ClinicalTrials.gg
CompletedNCT01453426109HV108Updated Sep 16, 2013

Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers

A Phase 1 interventional study of BG00012 Dose 1 and BG00012 Dose 2 in Healthy, sponsored by Biogen. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-09-16.

Sponsored by Biogen · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is an open-label, parallel-group study to evaluate the PK, safety, and tolerability of two different dose regimens of BG00012 over a 24-hour period to adult Chinese, Japanese, and Caucasian healthy volunteers.

Read the detailed description

The purpose of this healthy volunteer study is to provide pharmacokinetic and safety data for two different dose regimens of BG00012. The study will evaluate BG00012 administered over a 24-hour period.

The study will be conducted in male and female Chinese, Japanese, and Caucasian healthy volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must give written and any authorizations required by local law
  • All subjects must practice effective during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • History of any cardiac, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, and renal, or other major disease, as determined by the Investigator.
  • History of (subjects with basal cell carcinoma that has been completely excised prior to study entry remain eligible)
  • History of severe allergic or anaphylactic reactions
  • Known history of or positive test result for (HIV)
  • Serious infection (e.g., pneumonia, septicemia) within 2 months prior to Screening.
  • Female subjects who are pregnant or currently breastfeeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Chinese Subjects - Dose 1 BG00012

    Drug: BG00012 Dose 1

  • Experimental
    Chinese Subjects - Dose 2 BG00012

    Drug: BG00012 Dose 2

  • Experimental
    Japanese Subjects - Dose 1 BG00012

    Drug: BG00012 Dose 1

  • Experimental
    Japanese Subjects - Dose 2 BG00012

    Drug: BG00012 Dose 2

  • Experimental
    Caucasian Subjects - Dose 1 BG00012

    Drug: BG00012 Dose 1

  • Experimental
    Caucasian Subjects - Dose 2 BG00012

    Drug: BG00012 Dose 2

Interventions

06

What researchers measure

Primary outcomes

  1. AUC of BG00012

    Time frame: First dose to 24 hours

  2. Cmax of BG00012

    Time frame: First dose to 24 hours

Secondary outcomes

  1. Number of Adverse Events, as a measure of safety and tolerability

    Time frame: Subjects will be followed for the duration of the study, an expected 20 days

  2. Number of Serious Adverse Events, as a measure of safety and tolerability

    Time frame: Subjects will be followed for the duration of the study, an expected 20 days

07

Study locations

2 sites
  • Research Site
    Melbourne, Victoria, Australia
  • Research Site
    Hong Kong, Hong Kong, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2011
First posted
Oct 17, 2011
Start
Jan 2012
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Last update
Sep 16, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01453426
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Oct 17, 2011
Start date
Jan 2012
Primary completion
Apr 2012
Completion
Apr 2012
Last update
Sep 16, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion